Member Posts > Cardiol Therapeutics' CRD-38: A Game-Changing Therapeutic Innovation in Heart Failure, Backed by JACC
🩺 Cardiol Therapeutics (NASDAQ: CRDL) is making strides in heart failure (HF) treatment with its investigational therapy, CRD-38. Newly published data in JACC supports its ability to significantly improve cardiac function by addressing the underlying mechanisms of HF.
CRD-38's Unique Mechanism of Action
CRD-38 is a dual-mechanism therapy that stands out from traditional HF treatments by:
✔ Reducing Inflammation & Fibrosis - Targeting CB1 & CB2 receptors to combat chronic inflammation in cardiac tissue.
✔ Enhancing Vascular Health - Organic nitrates induce vasodilation, improving oxygen supply to the heart muscle.
🔬 Key Preclinical Findings:
📈 Increased Ejection Fraction - Strengthening the heart's pumping efficiency.
📉 Reduced Hypertrophy & Fibrosis - Slowing disease progression and structural damage.
💡 Why CRD-38 Matters
With heart failure affecting millions worldwide, CRD-38's subcutaneous formulation could enhance treatment efficacy and patient compliance compared to existing oral medications.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx